Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$3.24 USD
+0.09 (2.85%)
Updated Sep 16, 2024 11:42 AM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Aprea Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 113 | 37 | 53 | 30 |
Income After Depreciation & Amortization | -15 | -113 | -37 | -53 | -30 |
Non-Operating Income | 1 | 1 | 0 | -1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -113 | -37 | -53 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -113 | -37 | -53 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -113 | -37 | -53 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -113 | -37 | -53 | -29 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -15 | -113 | -37 | -53 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.62 | 1.66 | 1.06 | 1.06 | 0.30 |
Diluted EPS Before Non-Recurring Items | -3.95 | -31.75 | -34.80 | -50.60 | -93.40 |
Diluted Net EPS (GAAP) | -3.95 | -67.99 | -34.80 | -50.60 | -93.40 |
Fiscal Year end for Aprea Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.56 | 0.38 | 0.01 | 0.32 | 0.25 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.56 | 0.38 | 0.01 | 0.32 | 0.25 |
SG&A, R&D, and Dept/Amort Expenses | 4.41 | 3.53 | 3.69 | 3.84 | 3.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.85 | -3.15 | -3.68 | -3.52 | -3.65 |
Non-Operating Income | 0.38 | 0.34 | 0.23 | 0.32 | 0.39 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -3.47 | -2.81 | -3.44 | -3.20 | -3.26 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.47 | -2.81 | -3.44 | -3.20 | -3.26 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.47 | -2.81 | -3.44 | -3.20 | -3.26 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5.94 | 4.20 | 3.74 | 3.74 | 3.73 |
Diluted EPS Before Non-Recurring Items | -0.58 | -0.67 | -0.92 | -0.86 | -0.87 |
Diluted Net EPS (GAAP) | -0.58 | -0.67 | -0.88 | -0.86 | -0.87 |